The management of advanced-stage Hodgkin lymphoma has entered an era defined by immune-based therapy. Nivolumab-AVD has become the preferred frontline regimen, delivering high cure rates with minimal toxicity across age groups. BrECADD remains an effective, fe... ...

请注册登录后继续浏览